JP2005500351A5 - - Google Patents

Download PDF

Info

Publication number
JP2005500351A5
JP2005500351A5 JP2003517018A JP2003517018A JP2005500351A5 JP 2005500351 A5 JP2005500351 A5 JP 2005500351A5 JP 2003517018 A JP2003517018 A JP 2003517018A JP 2003517018 A JP2003517018 A JP 2003517018A JP 2005500351 A5 JP2005500351 A5 JP 2005500351A5
Authority
JP
Japan
Prior art keywords
mixture
water
atorvastatin calcium
crystalline form
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003517018A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005500351A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/000431 external-priority patent/WO2003011826A1/en
Publication of JP2005500351A publication Critical patent/JP2005500351A/ja
Publication of JP2005500351A5 publication Critical patent/JP2005500351A5/ja
Pending legal-status Critical Current

Links

JP2003517018A 2001-07-30 2002-01-07 結晶形態viおよびviiのアトルバスタチンカルシウム Pending JP2005500351A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN620MA2001 2001-07-30
PCT/US2002/000431 WO2003011826A1 (en) 2001-07-30 2002-01-07 Crystalline forms vi and vii of atorvastatin calcium

Publications (2)

Publication Number Publication Date
JP2005500351A JP2005500351A (ja) 2005-01-06
JP2005500351A5 true JP2005500351A5 (cg-RX-API-DMAC7.html) 2005-10-27

Family

ID=35160889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003517018A Pending JP2005500351A (ja) 2001-07-30 2002-01-07 結晶形態viおよびviiのアトルバスタチンカルシウム

Country Status (19)

Country Link
EP (2) EP1414796A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005500351A (cg-RX-API-DMAC7.html)
KR (1) KR20040019043A (cg-RX-API-DMAC7.html)
CN (1) CN100471836C (cg-RX-API-DMAC7.html)
AU (1) AU2002255479B2 (cg-RX-API-DMAC7.html)
BG (1) BG108518A (cg-RX-API-DMAC7.html)
BR (1) BR0211488A (cg-RX-API-DMAC7.html)
CA (1) CA2454500C (cg-RX-API-DMAC7.html)
CZ (1) CZ2004126A3 (cg-RX-API-DMAC7.html)
EE (1) EE200400048A (cg-RX-API-DMAC7.html)
HR (1) HRP20040077A2 (cg-RX-API-DMAC7.html)
IL (2) IL159626A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04000889A (cg-RX-API-DMAC7.html)
NO (1) NO20040390L (cg-RX-API-DMAC7.html)
NZ (1) NZ530785A (cg-RX-API-DMAC7.html)
PL (1) PL368647A1 (cg-RX-API-DMAC7.html)
RU (1) RU2304139C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003011826A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200400573B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
CN1535139A (zh) * 2000-11-03 2004-10-06 ������ҩ��ҵ���޹�˾ 阿伐他丁半钙形式ⅶ
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2431068C (en) * 2000-12-27 2008-06-10 Ciba Specialty Chemicals Holding Inc. Crystalline forms of atorvastatin
PL372303A1 (en) * 2002-02-15 2005-07-11 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
JP4422488B2 (ja) 2002-02-19 2010-02-24 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンヘミカルシウム溶媒和物の脱溶媒和法及び有機溶媒を本質的に含まないアトルバスタチンヘミカルシウム
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
EP1572643A2 (en) * 2002-11-28 2005-09-14 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
EP1761489A1 (en) * 2004-03-17 2007-03-14 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
CA2560252C (en) 2004-03-17 2009-08-04 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
WO2006008091A2 (en) * 2004-07-16 2006-01-26 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2754932C (en) 2004-07-20 2014-04-01 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
TW200825092A (en) 2004-09-28 2008-06-16 Teva Pharma A method for reducing the level of AED in atorvastatin calcium sample
MX2007004722A (es) 2004-10-28 2007-06-15 Warner Lambert Co Procedimiento para formar atorvastatina amorfa.
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
US8080672B2 (en) 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
EP2185527A2 (en) * 2007-07-11 2010-05-19 Actavis Group PTC EHF Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN104983702A (zh) * 2015-07-23 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
CN108157405B (zh) * 2018-02-06 2020-10-02 上海应用技术大学 一种灭蟑螂饵剂及其制备方法和应用
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
IL109570A0 (en) * 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
BR9609872A (pt) 1995-07-17 1999-03-23 Warner Lambert Co Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US5929156A (en) 1997-05-02 1999-07-27 J.M. Huber Corporation Silica product for use in elastomers
HU226640B1 (en) 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
SI1535613T1 (sl) * 1999-11-17 2010-12-31 Teva Pharma Postopek za pripravo polimorfne oblike atorvastatin kalcija
CN1535139A (zh) * 2000-11-03 2004-10-06 ������ҩ��ҵ���޹�˾ 阿伐他丁半钙形式ⅶ
HRP20030454A2 (en) * 2000-11-16 2005-10-31 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-(3,6-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2431068C (en) * 2000-12-27 2008-06-10 Ciba Specialty Chemicals Holding Inc. Crystalline forms of atorvastatin
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)

Similar Documents

Publication Publication Date Title
RU2004103470A (ru) Кристаллические формы vi и vii кальциевой соли аторвастатина
KR100431038B1 (ko) 결정질[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산 헤미 칼슘염 (아토르바스타틴)
US5103024A (en) Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
SK5898A3 (en) Novel process for the production of amorphous [r-(r*,r*)]-2-(4- -fluorophenyl)-'beta','delta'-dihydroxy-5-(1-methylethyl)-3- -phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
BG63629B1 (bg) Кристална форма iii на хемикалциева сол на [r-(r*,r*)]-2-(4-флуорофенил)-бета,делта-дихидрокси-5-(1-метил eтил)-3-фенил-4-[(фениламино)карбонил]-1н-пирол-1-хептанова киселина (аторвастатин)
CA2392025A1 (en) Process for the preparation of amorphous atorvastatin
SK109095A3 (en) Method of production of trans-6-£2-(substituted-pyrol-1-yl)alkyl| pyran-2-one intermediates of this method and pharmaceutical agents
SK7212003A3 (en) Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy- 5-(1-methylethyl)-3-fenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1- heptanoic acid esters with calcium hydroxide
JP2004516311A (ja) アトルバスタチン結晶体
AU2002255479A1 (en) Crystalline forms VI and VII of atorvastatin clacium
CA2456095A1 (en) An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
CA2564030A1 (en) Salt forms of [r-(r*, r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
WO2007099552A2 (en) Novel crystalline form of atovastatin hemi-magnesium
US20090240064A1 (en) Crystalline form of atorvastatin hemi-calcium
AU1548099A (en) Process for the preparation of 1-aryl-5-(perfluoroalkyl) pyrrole compounds rom N-(perfluoroalkylmettyl) arylimidoyl chloride compounds
US20040242899A1 (en) Crystalline forms VI and VII of atrovastatin calcium
SI21745A (sl) Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina
JP2012031130A (ja) アトルバスタチンヘミカルシウム塩の新規な結晶形、その水和物、及びその製造方法
KR101012917B1 (ko) 피롤 헵탄산 화합물의 신규한 결정형
JP2005505572A (ja) アトルバスタチンの調整用中間体である1−ピロール誘導体の多形体
WO2008053495A1 (en) A novel crystalline form of atorvastatin sodium
JP4143740B2 (ja) 置換ピリミジン誘導体の製造方法
JP2007500202A (ja) Hmg−coaレダクターゼ阻害剤である置換ピロール誘導体
ZA200603338B (en) Method for producing (3-oxo-2,3-dihydro-1H-isoindol-1yl) acetylguanidine derivatives
EP2130819A2 (en) Crystalline forms of atorvastatin magnesium